SETD2 and myelodysplastic syndrome: Although additional studies are needed to elucidate the biological importance of SETD2 mutations in MDS, our data provided insights into the role of SETD2 in MDS and suggested that this gene may be a novel therapeutic target in MDS, as well as other human cancers with SETD2 deficiency.